# Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

> **NCT02854761** · PHASE1 · UNKNOWN · sponsor: **Efranat Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Recurrent Respiratory Papillomatosis

## Interventions

- **DRUG:** EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

## Key facts

- **NCT ID:** NCT02854761
- **Lead sponsor:** Efranat Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2018-09
- **Final completion:** —
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2016-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02854761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02854761, "Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02854761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*